KaydedilenlerDerginizi ekleyin

Dergiler / art / 2018 / Cilt: 33 - Sayı: 3

Sorafenib Reveals Anti-Arthritic Potentials in Collagen Induced Experimental Arthritis Model

NEVZAT GÖZEL
Maşallah ÇAKIRER
AHMET KARATAŞ
Mehmet TUZCU
FETHİ AHMET ÖZDEMİR
ADİLE FERDA DAĞLI
Kazım ŞAHİN
SÜLEYMAN SERDAR KOCA
Dergi
art
Sayfa
309–315
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Our findings indicate that sorafenib treatment ameliorates CIA with anti-VEGF effectiveness.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to examine the effects of sorafenib on a collagen-induced arthritis (CIA) model.
📊
Temel Bulgular & Veri:Materials and methods: The study included 50 randomly selected female Wistar-albino rats (8-10-week-old, weighing between 200 g to 250 g).
💡
Sonuç & Katkı:Conclusion: Our findings indicate that sorafenib treatment ameliorates CIA with anti-VEGF effectiveness.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: This study aims to examine the effects of sorafenib on a collagen-induced arthritis (CIA) model. Materials and methods: The study included 50 randomly selected female Wistar-albino rats (8-10-week-old, weighing between 200 g to 250 g). The rats were divided into five equal groups as control, arthritis, etanercept, sorafenib high-dose, and sorafenib low-dose groups, respectively. Arthritis was induced by injecting mixed intradermal chicken type II collagen and incomplete Freund's adjuvant. Twenty-four hours after the advent of arthritis; rats in group 3 were injected subcutaneous etanercept (6 mg/kg/week), while those in groups 4 and 5 were given sorafenib (10 or 30 mg/kg/day) orally until they were sacrificed on the 34th day. The rat claws and trunk bloods were carefully examined to note perisynovial inflammation and cartilage/bone injury through histopathology. Tissue vascular endothelial growth factor (VEGF) and VEGF receptor levels were carefully checked using western blot analysis. Results: Analysis of the experimental data showed that CIA decreased in treatments groups after 12-13 days and 34th day in contrast with the arthritis group. Histopathological examination revealed broad perisynovial inflammation and cartilage/bone break down in the arthritis group. Compared to the control group, tissue VEGF and VEGF receptor levels increased in the arthritis group. Sorafenib and etanercept decreased tissue VEGF and VEGF receptor levels, perisynovial inflammation, damage of cartilage/bone. Conclusion: Our findings indicate that sorafenib treatment ameliorates CIA with anti-VEGF effectiveness.

🔖

Bu Makaleye Atıf Yap

GÖZEL, N., ÇAKIRER, M., KARATAŞ, A., TUZCU, M., ÖZDEMİR, F. A., DAĞLI, A. F., ŞAHİN, K., KOCA, S. S. (2018). Sorafenib Reveals Anti-Arthritic Potentials in Collagen Induced Experimental Arthritis Model. art, Cilt: 33 - Sayı: 3, 309–315. https://ajindex.com/articles/156445

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 2002;979:80-93.
  2. Ballara S, Taylor PC, Reusch P, Marmé D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001;44:2055-64.
  3. Sone H, Sakauchi M, Takahashi A, Suzuki H, Inoue N, Iida K, et al. Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci 2001;69:1861-9.
  4. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/ endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
  5. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998;27:377-80.
  6. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis J Immunol 1994;152:4149-56.
  7. Kucharz EJ, Gozdzik J, Kopec M, Kotulska A, Lewicki M, Pieczyrak R, et al. A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis. Clin Exp Rheumatol 2003;21:273-4.
  8. Nagashima M, Wauke K, Hirano D, Ishigami S, Aono H, Takai M, et al. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1255-62.
  9. Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001;19:321-4
  10. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006;12:5018-22. Taylor PC. VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res 2002;4:99-107.
  11. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
  12. Barsante MM, Roffê E, Yokoro CM, Tafuri WL, Souza DG, Pinho V, et al. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of